Patents by Inventor Benjamin R. TAFT
Benjamin R. TAFT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250011334Abstract: The invention provides compounds of Formula (1): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.Type: ApplicationFiled: June 13, 2024Publication date: January 9, 2025Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
-
Patent number: 11912715Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.Type: GrantFiled: July 13, 2021Date of Patent: February 27, 2024Assignee: Novartis AGInventors: Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
-
Publication number: 20220041610Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.Type: ApplicationFiled: July 13, 2021Publication date: February 10, 2022Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
-
Patent number: 10709712Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: February 12, 2019Date of Patent: July 14, 2020Assignee: NOVARTIS AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
-
Patent number: 10392404Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: September 11, 2015Date of Patent: August 27, 2019Assignee: Novartis AGInventors: Paul Andrew Barsanti, Matthew T. Burger, Yan Lou, Gisele A. Nishiguchi, Valery Rostislavovich Polyakov, Savithri Ramurthy, Sharadha Subramanian, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
-
Publication number: 20190175606Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: February 12, 2019Publication date: June 13, 2019Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
-
Patent number: 10245267Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: May 22, 2017Date of Patent: April 2, 2019Assignee: Novartis AGInventors: Robert John Aversa, Paul Andrew Barsanti, Matthew T. Burger, Michael Patrick Dillon, Alan Dipesa, Cheng Hu, Yan Lou, Gisele A. Nishiguchi, Yue Pan, Valery Rostislavovich Polyakov, Savithri Ramurthy, Alice C. Rico, Lina Quattrocchio Setti, Aaron Smith, Sharadha Subramanian, Benjamin R. Taft, Huw Roland Tanner, Lifeng Wan, Naeem Yusuff
-
Patent number: 10167279Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: September 11, 2015Date of Patent: January 1, 2019Assignee: Novartis AGInventors: Robert John Aversa, Matthew T. Burger, Michael Patrick Dillon, Thomas A. Dineen, Jr., Yan Lou, Gisele A. Nishiguchi, Savithri Ramurthy, Alice C. Rico, Vivek Rauniyar, Martin Sendzik, Sharadha Subramanian, Lina Quattrocchio Setti, Benjamin R. Taft, Huw Rowland Tanner, Lifeng Wan
-
Patent number: 10160764Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.Type: GrantFiled: August 25, 2017Date of Patent: December 25, 2018Assignee: Novartis AGInventors: Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
-
Publication number: 20180170917Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: September 11, 2015Publication date: June 21, 2018Inventors: Robert John AVERSA, Matthew T. BURGER, Michael Patrick DILLON, Thomas A. DINEEN, Jr., Yan LOU, Gisele A. NISHIGUCHI, Savithri RAMURTHY, Alice C. RICO, Vivek RAUNIYAR, Martin SENDZIK, Sharadha SUBRAMANIAN, Lina Quattrocchio SETTI, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
-
Publication number: 20180057501Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.Type: ApplicationFiled: August 25, 2017Publication date: March 1, 2018Inventors: Rama JAIN, Dennis Christofer KOESTER, James R. MANNING, Vanessa MARX, Daniel POON, James Clifford SUTTON, Benjamin R. TAFT, Lifeng WAN, Aregahegn YIFRU, Qian ZHAO
-
Patent number: 9809610Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: January 4, 2017Date of Patent: November 7, 2017Assignee: Novartis AGInventors: Matthew T. Burger, Savithri Ramurthy, Benjamin R. Taft
-
Publication number: 20170260200Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: September 11, 2015Publication date: September 14, 2017Inventors: Paul Andrew BARSANTI, Matthew T. BURGER, Yan LOU, Gisele A. NISHIGUCHI, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Rowland TANNER, Lifeng WAN
-
Publication number: 20170260207Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: May 22, 2017Publication date: September 14, 2017Inventors: Robert John AVERSA, Paul Andrew BARSANTI, Matthew T. BURGER, Michael Patrick DILLON, Alan DIPESA, Cheng HU, Yan LOU, Gisele A. NISHIGUCHI, Yue PAN, Valery Rostislavovich POLYAKOV, Savithri RAMURTHY, Alice C. RICO, Lina Quattrocchio SETTI, Aaron SMITH, Sharadha SUBRAMANIAN, Benjamin R. TAFT, Huw Roland TANNER, Lifeng WAN, Naeem YUSUFF
-
Publication number: 20170114083Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: January 4, 2017Publication date: April 27, 2017Applicant: NOVARTIS AGInventors: Matthew T. BURGER, Savithri RAMURTHY, Benjamin R. TAFT
-
Patent number: 9573969Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: GrantFiled: September 11, 2015Date of Patent: February 21, 2017Assignee: NOVARTIS AGInventors: Matthew T. Burger, Savithri Ramurthy, Benjamin R. Taft
-
Publication number: 20160075727Abstract: The present invention provides a compound of Formula I: wherein X, Y, Z, R1 and R2 are as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with RAF kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.Type: ApplicationFiled: September 11, 2015Publication date: March 17, 2016Applicant: Novartis AGInventors: Matthew T. Burger, Savithri RAMURTHY, Benjamin R. TAFT